About Prof. Dr. Med. Claus Belka
Prof. Dr. Med. Claus Belka is a globally recognised Radiation Oncologist in Munich and one of Germany's leading authorities in radiotherapy and clinical radiation oncology. With over 30 years of academic and clinical experience, he is internationally regarded for advanced radiation therapy in solid tumours and translational research in apoptosis and radiation-induced cell death.
- 30+ years of experience in Radiation Oncology and Radiotherapy
- Editor-in-Chief of the international journal Radiation Oncology
- Recipient of the Hermann Holthusen Prize, German Society of Radiation Oncology
- Listed by FOCUS as one of Germany's top radiotherapy specialists
- Expert in IMRT, VMAT, MR-Linac, stereotactic radiosurgery and brachytherapy
Qualifications & Credentials
Medical Degrees
- Study of Human Medicine — University of Essen, Germany, 1986–1993
- Doctoral Degree — Faculty of Human Genetics, University of Essen, Germany
- Habilitation in Radiation Oncology — Eberhard Karls University of Tübingen, Germany
Fellowships & Special Training
- Assistant Physician, Hematology and Oncology — Campus Benjamin Franklin, Charité University Hospital Berlin and Robert Rössle Clinic, Berlin, 1993–1995
- Research training in experimental radiotherapy — Eberhard Karls University of Tübingen
Certifications & Accreditations
- German Board Certification — Radiation Oncology & Radiotherapy
- Member — German Society of Radiation Oncology (DEGRO)
- Member — European Society for Radiotherapy and Oncology (ESTRO)
Areas of Expertise
Major Conditions Treated
- Breast Cancer
- Prostate Cancer and Urological Malignancies
- Lung & Mediastinal Cancer
- Brain & Spinal Cord Tumours
- Head & Neck Cancers
- Gastrointestinal Tumours (including Hepatocellular Carcinoma)
- Lymphomas and Leukaemia
- Gynaecological Cancers
- Bone & Soft Tissue Sarcomas
- Skin Tumours
Sub-specialties
- Image-Guided & Adaptive Radiotherapy: Expert in IMRT, VMAT and MR-Linac technology — making him a sought-after Radiation Oncologist in Munich, Germany for patients seeking advanced cancer radiotherapy in Europe.
- Stereotactic Radiosurgery: Brain and lung stereotactic ablative therapy for early-stage and metastatic disease.
- Translational Radiation Research: Apoptosis biology, radiation-induced cell death and combination therapy with TRAIL receptor agonists.
Advanced Procedures & Treatments
- Intensity-Modulated Radiation Therapy (IMRT)
- Volumetric Modulated Arc Therapy (VMAT)
- Image-Guided Radiation Therapy (IGRT)
- MR-Linac Guided Adaptive Radiotherapy
- Stereotactic Radiosurgery (Brain & Body)
- Brachytherapy
- Total Body Irradiation
- Catheter-Based Afterloading Therapy
- 225Ac-PSMA-I&T Targeted Alpha Therapy (advanced mCRPC)
List of Disease and Treatment for which Prof. Dr. Med. Claus Belka can be consulted
Professional Experience
Current Affiliation
- University Hospital of Ludwig Maximilian University (LMU Klinikum), Munich, Germany — Director, Department of Radiation Therapy and Radiation Oncology, 2008–Present
- Ludwig-Maximilians-Universität, Munich, Germany — Chair of Radiotherapy, Faculty of Medicine
Past Affiliations
- Eberhard Karls University of Tübingen, Germany — Deputy Head, Department of Radiation Oncology, 2004–2008
- Eberhard Karls University of Tübingen, Germany — Head, Research Group on Experimental Radiotherapy, 2007–2008
- Charité University Hospital Berlin / Robert Rössle Clinic, Berlin, Germany — Assistant Physician, Hematology and Oncology, 1993–1995
Academic & Research Roles
- Editor-in-Chief — Radiation Oncology (BMC journal)
- Principal Investigator — Apoptosis and radiation biology research at LMU Munich
- Faculty — Munich Cluster for Systems Neurology (SyNergy) collaborator
Key Achievements
- 30+ years in radiation oncology research and clinical practice
- Hermann Holthusen Prize — German Society of Radiation Oncology
- FOCUS list — Top doctors for radiation therapy in Germany
- One of only three centres in Germany operating MR-Linac technology under his department
- 500+ peer-reviewed publications and over 30,000 citations on Google Scholar
Awards & Recognitions
National & International Awards
- Hermann Holthusen Prize — German Society of Radiation Oncology (DEGRO)
- FOCUS Magazine — Top Physician for Radiotherapy in Germany (multiple years)
- Editor-in-Chief — Radiation Oncology, since 2006
Professional Memberships
- German Society of Radiation Oncology (DEGRO)
- European Society for Radiotherapy and Oncology (ESTRO)
- American Society for Radiation Oncology (ASTRO)
- German Cancer Society (DKG)
Research & Publications
Published Papers (Selected)
- Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. "Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo." Oncogene. 2006.
- Belka C, Theissen SM. "Radiation Oncology reviewer acknowledgement 2015." Radiat Oncol. 2016 Feb 26;11(1):27.
- Belka C, et al. "PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced mCRPC patients." (First clinical results).
- Belka C, et al. Multiple publications on glioblastoma re-irradiation, 4-miRNA risk signatures, and stereotactic brachytherapy outcomes — LMU Munich, multiple years.
Ongoing Research & Clinical Interests
- Apoptosis and radiation-induced cell death
- MR-Linac adaptive radiotherapy
- Glioblastoma re-irradiation strategies
- Targeted alpha therapy in metastatic prostate cancer
- Combination of immunotherapy and radiotherapy
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Initial Radiation Oncology Consultation | ₹25,000 – ₹60,000 | $300 – $720 |
| IMRT / VMAT (full course) | ₹6,00,000 – ₹15,00,000 | $7,200 – $18,000 |
| Stereotactic Radiosurgery (SRS/SBRT) | ₹5,00,000 – ₹14,00,000 | $6,000 – $16,800 |
| MR-Linac Adaptive Radiotherapy | ₹10,00,000 – ₹25,00,000 | $12,000 – $30,000 |
| Brachytherapy | ₹2,50,000 – ₹8,00,000 | $3,000 – $9,600 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Prof. Dr. Med. Claus Belka use in Radiation Oncology treatment?
Prof. Belka uses MR-Linac technology, IMRT, VMAT, image-guided radiation therapy, brain and lung stereotactic radiosurgery, total body irradiation, brachytherapy and catheter-based afterloading. His department also pioneers 225Ac-PSMA targeted alpha therapy for advanced prostate cancer.
2. What conditions does Prof. Dr. Med. Claus Belka specialize in treating?
Prof. Belka specialises in radiation therapy for breast cancer, prostate cancer, lung cancer, brain tumours, head & neck cancers, gastrointestinal tumours, lymphomas, gynaecological malignancies and sarcomas — making him a leading Radiation Oncologist in Munich, Germany for patients seeking advanced cancer radiotherapy in Europe.
3. How do I book an appointment with Prof. Dr. Med. Claus Belka?
Appointments with Prof. Dr. Med. Claus Belka can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Prof. Dr. Med. Claus Belka?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Prof. Dr. Med. Claus Belka, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Prof. Dr. Med. Claus Belka offer second opinions for Radiation Oncology cases?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert Radiation Oncologist in Munich, Germany.
University Hospital Rechts der Isar - Germany
